1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : Drug Product Services Participates in the RealHOPE Project to Assess and Improve Protein Stability

01/19/2022 | 08:12am EDT
  • Lonza Drug Product Services is participating in the RealHOPE project to identify critical factors contributing to protein instability during handling
  • The program aims to develop tools for assessing protein stability during handling, distribution, and administration with the goal to improve the control of storage and transportation of drugs
  • Lonza has initiated the first project activities of the RealHOPE program

Basel, Switzerland, 19 January 2022 - Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today that its Drug Product Services is participating in the Real-World Handling of Protein Drugs - Exploration, Evaluation and Education (RealHOPE) project. This initiative, originated by the Innovative Medicines Initiative and European Federation of Pharmaceutical Industries and Associations (EFPIA) partners, aims to measure real-life events during drug handling that can destabilize protein-based therapeutics.

Assessing protein stability in formulations is necessary for process optimization and ensuring the quality and safety of therapies. It is well known that vibrations, heat, or sunlight exposure affect the stability of proteins. However, little is known about the effects that handling during storage, distribution, and administration has on these products.

The RealHOPE project was initiated to bring together experts from the industry, logistic enterprises, hospital pharmacies, and patient organizations to significantly improve the efficiency and effectiveness of the drug development process. The long-term aim is to ensure that the pharmaceutical sector produces more effective and safer innovative medicines for patients. The consortia have initiated the first project activities, namely the start of the surveys among hospital professionals and patients at home on their use and handling of protein drugs.

Ahmad Sediq, Senior Group Leader, Formulation Development, Drug Product Services, Lonza commented:"Over the past 20 years there have been numerous cases of severe adverse reactions or even deaths associated with improper and/or erroneous drug preparations in hospitals. Due to their sensitive nature, handling of protein-based solutions may jeopardize their quality by increasing levels of physical instabilities through aggregation or chemical degradation, such as oxidation. These impurities can lead to adverse drug reactions and/or alteration in the drug effectiveness. By becoming part of the RealHOPE Project, our goal is to thoroughly map out the real-life handling of these drugs in clinical practice or at a patient's home, to develop simulation models and analytical methodologies to assess the impact of the handling on product quality and introduce best practices to control or avoid these stability and efficacy challenges."

The project plans to utilize smart technologies to track light and heat exposure, shear stress and shock during real-life protein handling, as well as analyze related protein degradation. The data and process understanding obtained will be used to develop educational materials for clinicians, pharmacies, caregivers, and patients. The project also intends to open a dialogue with the regulatory bodies to create visibility for the challenges the pharmaceutical manufacturers are facing. The ultimate goal is to develop more robust processes, simulation models and analytical methods for ensuring safer protein-based therapies.

Peter Droc, Head Drug Product Services, Lonza, added:"Ensuring that protein-based therapeutics remain stable throughout the entire manufacturing, distribution, and administration cycle is critical in developing safe and efficacious therapies. Our participation in this consortium represents a key enabler to develop and optimize knowledge and tools addressing the stability issue and, ultimately, to offer increased levels of stability control to our customers."

Disclaimer

Lonza Group Ltd. published this content on 19 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2022 13:11:09 UTC.


© Publicnow 2022
All news about LONZA GROUP AG
05/25Lonza and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics an..
AQ
05/24Lonza Ties Up With Israel Biotech Fund On Biologics, Small Molecule Development, Manufa..
MT
05/24LONZA : and Israel Biotech Fund Collaboration Framework Agreement to Support Biologics and..
PU
05/23Switzerland's Lonza to Scale Up Inhalation Capabilities at US Site
MT
05/23LONZA : to Expand Inhalation Capabilities at Tampa Site
PU
05/18Lonza Opens New Facility for Kodiak Sciences' Retinal Diseases Drug
MT
05/09Lonza, ALSA Ventures Partner To Support Development Of Small Molecule Drug Candidates
MT
05/09LONZA GROUP AG : Ex-dividend day for Distribution from share premium account
FA
05/09LONZA GROUP AG : Ex-dividend day for final dividend
FA
05/06EuroAPI gains on market debut after spin-off from Sanofi
RE
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 152 M 6 433 M 6 433 M
Net income 2022 1 064 M 1 112 M 1 112 M
Net cash 2022 423 M 442 M 442 M
P/E ratio 2022 39,9x
Yield 2022 0,58%
Capitalization 42 496 M 44 437 M 44 437 M
EV / Sales 2022 6,84x
EV / Sales 2023 6,09x
Nbr of Employees 16 218
Free-Float 98,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 572,80 CHF
Average target price 796,79 CHF
Spread / Average Target 39,1%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Stefan Stoffel Head-Small Molecules Exclusive Synthesis Operation
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-24.79%44 437
MODERNA, INC.-41.86%58 733
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478
CELLTRION, INC.-21.21%17 245